Eczemus®Ointment
(Tacrolimus)

Tacrolimus is first FDA approved steroid free topical preparation for management of Eczema.
Eczemus (Tacrolimus) is a macrolide immunosuppressant produced by streptomyces tsukubaensis. Eczemus (Tacrolimus) inhibits T-lymphocyte activation by first binding to an intracellular protein,FKBP-12. Eczemus (Tacrolimus) has also been shown to inhibit the release of inflammatory mediators from skin mast cells, basophils and eosinophils. Eczemus (Tacrolimus) ointment does not affect collagen synthesis in humans.

  • Eczemus (Tacrolimus) Ointment 0.03% is indicated for short-term and intermittent long-term therapy in the treatment of moderate to severe atopic dermatitis (eczema) in children.
  • Eczemus (Tacrolimus) Ointment 0.1% is indicated for short-term and intermittent long-term therapy in the treatment of moderate to severe atopic dermatitis (eczema) in adults.

Eczemus ointment 0.03% is supplied in the tube of 10g

Eczemus ointment 0.1% is supplied in the tube of 10g

Make an Inquiry